NCT04346862View on ClinicalTrials.gov

Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease

PHASE4UnknownINTERVENTIONAL
Enrollment

636

Participants

Timeline

Start Date

January 26, 2016

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Mild Cognitive Impairment
Interventions
DRUG

Acetyl-L-carnitine hydrochloride 500mg

The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks

DRUG

Placebo

The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks

Trial Locations (1)

Unknown

RECRUITING

Catholic Kwandong University International St. Mary'S Hospital, Incheon

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT04346862 - Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease | Biotech Hunter | Biotech Hunter